


Serial No. 10/629,466
Attorney Docket No. IN01481KB

Presently Pending Claims


Language to be added has been bolded and underlined, while language to be deleted has been ~~bolded and stricken through~~.

21. (Amended) A compound represented by the structural formula I




or a pharmaceutically acceptable salt or solvate thereof; wherein:

R¹ is



R² is selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkylketone, arylketone, alkyl, haloalkyl, cycloalkyl, ~~cycloheteroalkyl~~, cycloalkylalkyl, alkylsulfonyl, arylsulfonyl, alkoxyalkyl, or amide;

R³ is selected from the group consisting of ~~aryl~~, 6-membered heteroaryl, ~~fluorenyl~~, and ~~diphenylmethyl~~, 6-membered heteroaryl-N-oxide,



, wherein said ~~aryl~~, ~~fluorenyl~~, ~~diphenyl~~ or 6-membered heteroaryl or heteroaryl-N-oxide is pyrimidine or pyrimidine-N-oxide respectively, each of which is optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R¹¹, R¹², R¹³, R¹⁴ and R¹⁵;

R⁴ is 1-3 substituents selected from the group consisting of H, halo, alkyl, haloalkyl, alkoxy, cycloalkyl, amide, CF₃, OCF₃, aryl, heteroaryl, -XR⁷, -CN, -CO₂H, -CO₂R²², R⁸-aryl(C₁-C₆)alkyl-, R⁸-heteroaryl(C₁-C₆)alkyl-, -

Serial No. 10/629,466
Attorney Docket No. IN01481KB

$C(O)NR^{21}R^{22}$, $-C(O)NH_2$, wherein R^4 can be the same or different and is independently selected when there is more than one R^4 present;

~~R^5 is selected from the group consisting of H, arylalkyl, (C_4-C_6) alkyl, R^8 -aryl (C_4-C_6) alkyl, R^8 -heteroaryl (C_4-C_6) alkyl, $-SO_2-(C_4-C_6)$ alkyl, $-SO_2-(C_3-C_6)$ cycloalkyl, $-SO_2$ -aryl, R^8 -aryl- $-SO_2-$, $C(O)-(C_4-C_6)$ alkyl, $C(O)-(C_4-C_6)$ cycloalkyl, R^8 -aryl- $C(O)-$, $C(O)NR^{21}R^{22}$, and $-SO_2NR^{21}R^{22}$;~~

R^5 is H, (C_4-C_6) alkyl, or (C_4-C_6) haloalkyl;

R^7 is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R^8 is 1, 2 or 3 substituents selected from the group consisting of H, halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, $-CF_3$, $-OCF_3$, $CH_3C(O)-$, $-CN$, CH_3SO_2- ,

CF_3SO_2- and $-NH_2$, wherein R^8 can be the same or different and is independently selected when there are more than one R^8 present;

R^9 , R^{10} and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, and $-(C_1-C_6)$ haloalkyl;

R^{11} and R^{12} can be the same or different and are each independently selected from the group consisting of (C_1-C_6) alkyl, $-(C_1-C_6)$ haloalkyl, halogen, $-NR^{19}R^{20}$, $-OH$, CF_3 , $-OCH_3$, $-O$ -acyl, and $-OCF_3$;

R^{13} is selected from the group consisting of hydrogen, R^{11} , H, phenyl, $-NO_2$, $-CN$, $-CH_2F$, $-CHF_2$, $-CHO$, $-CH=NOR^{19}R^{20}$, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, $N(R^{20}R^{21})CONR^{20}R^{21}R^{22}R^{23}$, $-NHCONH$ (chloro- (C_1-C_6) alkyl), $-NHCONH((C_3-C_{10})$ -cycloalkyl (C_1-C_6) alkyl), $-NHCO(C_1-C_6)$ alkyl, $-NHCOCF_3$, $-NHCOCF_3$, $-NHSO_2N((C_1-C_6)$ alkyl) $_2$, $-NHSO_2(C_1-C_6)$ alkyl, $-N(SO_2CF_3)_2$, $-NHCO_2(C_1-C_6)$ alkyl, (C_3-C_{10}) cycloalkyl, $-SR^{22}$, $-SOR^{22}$, $-SO_2R^{22}$, $-SO_2NH(C_1-C_6)$ alkyl, $-OSO_2(C_1-C_6)$ alkyl, $-OSO_2CF_3$, hydroxy (C_1-C_6) alkyl, $-CONR^{19}R^{20}$, $-CON(CH_2CH_2-O-CH_3)_2$, $-OCONH(C_1-C_6)$ alkyl, $-CO_2R^{19}R^{20}$, $-Si(CH_3)_3$ and $-B(OC(CH_3)_2)_2$;

R^{14} is selected from the group consisting of (C_1-C_6) alkyl, $-(C_1-C_6)$ haloalkyl $-NH_2$ and R^{15} -phenyl;

R^{15} is 1-3 substituents selected from the group consisting of hydrogen, (C_1-C_6) alkyl, $-(C_1-C_6)$ haloalkyl, $-CF_3$, $-CO_2R^{20}$, $-CN$, (C_1-C_6) alkoxy and halogen; wherein R^{15} can be the same or different and is independently selected when there are more than one R^{15} present;

Serial No. 10/629,466
Attorney Docket No. IN01481KB

~~R¹⁶ and R¹⁷ can each be the same or different and are each independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or~~

~~R¹⁶ and R¹⁷ together are a C₂-C₅ alkylene group and with the carbon to which they are attached from a spiro ring of 3 to 6 carbon atoms;~~

R¹⁹, R²⁰ and R²¹ can each be the same or different and are each independently selected from the group consisting of H, (C₁-C₆)alkyl and (C₃-C₆)cycloalkyl;

R²² is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, (C₂-C₆)hydroxyalkyl, (C₂-C₆)alkylene, (C₃-C₆)cycloalkyl, aryl and aryl(C₁-C₆)alkyl-;

A is selected from the group consisting of H, (C₁-C₆)alkyl, and (C₂-C₆)alkenyl.










M is aryl ~~or heteroaryl~~ optionally substituted with R⁴;

~~Q is CH or N;~~ and


































X is selected from the group consisting of CH₂, SO₂, SO, S, and O, with the following proviso:

when R¹ is phenyl, ~~pyridyl, thiophenyl~~ or naphthyl, R² cannot be H, -(C₁-C₆)alkyl or -C(O)-(C₁-C₆)alkyl.





































22. (Amended) A compound having the structural formula I according to claim 21 wherein R⁹, R¹⁰ and B are H, A is -CH₃, and R¹, R² and R³ are as defined in the following table:

#	R ¹	R ²	R ³
8			
9			
10			





































Serial No. 10/629,466
Attorney Docket No. IN01481KB

11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			

Serial No. 10/629,466
Attorney Docket No. IN01481KB

22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			








































Serial No. 10/629,466
Attorney Docket No. IN01481KB

34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
46			


































Serial No. 10/629,466
Attorney Docket No. IN01481KB

50			
51			
52			
53			
58			
59			
60			
61			
62			
63			
65			
66			





































Serial No. 10/629,466
Attorney Docket No. IN01481KB

67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			



























Serial No. 10/629,466
Attorney Docket No. IN01481KB

80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			




Serial No. 10/629,466
Attorney Docket No. IN01481KB

91			
92			
93			
94			
95			
96			
97			
98			
99			
100			
101			
102			


































Serial No. 10/629,466
Attorney Docket No. IN01481KB

103			
104			
105			
106			
107			
108			
109			
110			
111		CH ₃	


































23. (Amended) A compound according to claim 22 wherein R¹, R² and R³ each represent:

#	R ¹	R ²	R ³
10			

























Serial No. 10/629,466
Attorney Docket No. IN01481KB

11			
12			
43			
14			
46			
17			
28			
29			
31			
36			
37			


Serial No. 10/629,466
Attorney Docket No. IN01481KB

39			
40			
50			
61			
68			
69			
70			
71			
80			
81			
82			





Serial No. 10/629,466
Attorney Docket No. IN01481KB

90			
91			
93			
96			
99			
100			
101			
102			


24. (Amended) A compound according to claim 23 represented by the structural formulae:



Serial No. 10/629,466
Attorney Docket No. LN01481KB



Serial No. 10/629,466
Attorney Docket No. IN01481KB



25. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 21.

26. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 24.

27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.

28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

29. (Previously presented) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

Serial No. 10/629,466
Attorney Docket No. IN01481KB

30. (Previously presented) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

31-40. (Previously canceled)